Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 7NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 206Glioblastoma 169Central Nervous System Neoplasms 138Astrocytoma 135Gliosarcoma 132Neuroblastoma 109Glioma 104Oligodendroglioma 87Medulloblastoma 68Sarcoma 51Neoplasms 45Ependymoma 43Osteosarcoma 40Wilms Tumor 39Familial ependymoma 38Neuroectodermal Tumors, Primitive, Peripheral 36Optic Nerve Glioma 33Breast Neoplasms 33Lymphoma, Non-Hodgkin 32Neurofibromatosis 1 31Choroid Plexus Neoplasms 29Lymphoma 28Burkitt Lymphoma 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Rhabdomyosarcoma 23Rhabdoid Tumor 23Recurrence 21Meningioma 21Carcinoma, Non-Small-Cell Lung 21Testicular Neoplasms 20

Interventions

cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sarcoma, Clear Cell × CNS × Clear all
NCT02867592 2026-05-27

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡